Status:
UNKNOWN
An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy
Lead Sponsor:
Xin Wu
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18-70 years
Brief Summary
This project intends to evaluate the sensitivity of different Homologous Recombination Deficiency (HRD) score to Poly(ADP-ribose) polymerase inhibitor (PARPi) by retrospectively analyzing the tissue s...
Eligibility Criteria
Inclusion
- age ≥ 18 years;
- high-grade serous/endometrioid epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer;
- FIGO stage III or IV;
- at least 6 cycles and no more than 9 cycles First-line platinum-containing chemotherapy;
- CR or PR after chemotherapy;
- ECOG 0-1;
- sufficient biological samples for HRD score detection;
- patients signed informed consent;
- good bone marrow function.
Exclusion
- incomplete follow-up records of survival information;
- unqualified biological sample quality control
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05255861
Start Date
March 1 2022
End Date
December 31 2024
Last Update
February 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Obstetrics and Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China, 200000